Literature DB >> 7432418

The FDA's critique of the anturane reinfarction trial.

R Temple, G W Pledger.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1980        PMID： 7432418     DOI： 10.1056/NEJM198012183032534

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  17 in total

Review 1.  Interpreting the results of secondary end points and subgroup analyses in clinical trials: should we lock the crazy aunt in the attic?

Authors:  N Freemantle
Journal:  BMJ       Date:  2001-04-21

2.  Statistics and ethics in medical research.

Authors:  David L DeMets
Journal:  Sci Eng Ethics       Date:  1999-01       Impact factor: 3.525

3.  Ascertainment of cause-specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee.

Authors:  Lorcan P McGarvey; Matthias John; Julie A Anderson; Michael Zvarich; Robert A Wise
Journal:  Thorax       Date:  2007-02-20       Impact factor: 9.139

Review 4.  North of England evidence based guideline development project: guideline on the use of aspirin as secondary prophylaxis for vascular disease in primary care. North of England Aspirin Guideline Development Group.

Authors:  M Eccles; N Freemantle; J Mason
Journal:  BMJ       Date:  1998-04-25

5.  'Pragmatic' and 'explanatory' attitudes to randomised trials.

Authors:  Merrick Zwarenstein
Journal:  J R Soc Med       Date:  2017-05       Impact factor: 5.344

Review 6.  Timolol after myocardial infarction: an answer or a new set of questions?

Authors:  J R Mitchell
Journal:  Br Med J (Clin Res Ed)       Date:  1981-05-16

7.  Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration.

Authors: 
Journal:  BMJ       Date:  1994-01-08

Review 8.  Current issues in thrombosis prevention with antiplatelet drugs.

Authors:  G de Gaetano; C Cerletti; E Dejana; J Vermylen
Journal:  Drugs       Date:  1986-06       Impact factor: 9.546

9.  Determination of sulfinpyrazone and four metabolites in plasma and urine by high pressure liquid chromatography.

Authors:  E G Lentjes; Y Tan; C A Van Ginneken
Journal:  Pharm Weekbl Sci       Date:  1985-12-13

10.  Sulphinpyrazone and renal function following myocardial infarction.

Authors:  S L Choudhury; S H Taylor; G Wieringa; R Swaminathan; D B Morgan
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.